A multi-centre randomised double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography

Table 1 Baseline patient characteristics

Characteristic	Placebo (n = 45)	Alfentanilb (n = 45)	P value
Male (%)	44.4 (20/45)	31.1 (14/45)	0.28
Age (years)	62.2	62.7	0.86
Weight (kg)	75.5	76.3	0.83
Height (cm)	172	170	0.41
BMI (kg/m2)	25.6	26.2	0.59
Education (%)			0.83
primary	6.7 (3/45)	6.7 (3/45)
secondary	53.3 (24/45)	46.7 (21/45)
tertiary	40.0 (18/45)	46.7 (21/45)
Ethnicity (%)			0.90
Dutch	93.3 (42/45)	91.1 (41/45)
Surinam	4.4 (2/45)	6.7 (3/45)
other	2.2 (1/45)	2.2 (1/45)
First CT colonography (%)	100 (45/45)	100 (45/45)	1.00
Indication abdominal pain (%)	29.5 (13/44)	15.9 (7/44)	0.20
Spasmolytic (%):			0.60
buscopan	86.7 (39/45)	84.4 (38/45)
glucagon	13.3 (6/45)	13.3 (6/45)
no	0 (0/45)	2.2 (1/45)
Oxygen saturation (%SpO2)	98	98	0.47
Heart rate (b/m)	77.8	79.0	0.70
Systolic blood pressure (mmHg)	155	158	0.59
Diastolic blood pressure (mmHg)	86	89	0.28
Expected burden (1–5)	3	3	0.31
Expected pain (1–5)	3	3	0.46

This table shows mean values, unless indicated otherwise; medians are presented for oxygen saturation, expected pain and burden.
For all percentage the numbers are given between brackets. No significant differences were present between baseline characteristics of the two groups.

ISSN: 1471-230X